AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening

    LOS ANGELES, July 16 /EMWNews-FirstCall/ -- Due to overwhelming

demand for ambulatory heart tests performed by the Athletes for Life

Foundation, Inc. ("AFL" or the "Foundation") using Signalife, Inc.'s (Amex:

SGN) award winning Fidelity 100 ECG system, AFL is returning to Ada,

Oklahoma, to perform more ECG tests at the request of the Chickasaw Nation

and members of the local community. Andrea Pogue MSN, RN, Industrial

Coordinator of the Pontotoc Technology Center ("PTC") of The Chickasaw

Nation, said, "We are so happy you all decided to come to PTC and bring the

trailer to perform life saving screenings."



    Willie Gault, Super Bowl champion, Olympic gold medalist, and winner of

the prestigious Jim Thorpe award, and one of the founders of Athletes For

Life, said, "After our last ECG screenings at the Pontotoc Technology

Center, performed as part of a program sponsored by the National Library of

Medicine (NLM), a division of the National Institute of Health's (NIH), we

were invited back to Ada, Oklahoma to expand our efforts to test both

numerous people we were unable to test on our first visit as well as many

new members of the public. In our first series of tests, we identified a

life threatening condition in a local 16 year old, which on its own

justifies our program. I plan to be back in Ada to help raise awareness

about heart disease and visit with the young man and his family."



    The Foundation is performing heart screening at its trailer at the Carl

Albert Hospital until Friday July 18, and will then move its trailer to the

Chickasaw Community Center to continue screening until July 26.



    Athletes for Life Foundation has continued to select Signalife's award

winning technology to perform its heart monitoring and screening. The

Signalife monitor is a 12 lead ambulatory ECG system capable of detecting

subtle ECG changes that may be significant for early diagnosis of potential

heart problems.

    About Athletes for Life Foundation



    The Athletes for Life Foundation, http://www.athletesforlife.com, is a

non-profit foundation whose membership includes a multitude of famous role

models and athletes who have witnessed friends and colleagues die suddenly

from cardiac disease. The Athletes for Life Foundation is committed to

promoting early diagnosis and treatment of cardiac disease in order to save

lives. The Athletes for Life Foundation is committed to bringing -- and

does bring -- new technologies to healthcare. The Athletes for Life

Foundation brings heart monitoring to communities, so that health care

comes to the masses and not vice versa, in its mission to "save lives, one

heart at a time."



    About Signalife



    Signalife, Inc., http://www.signalife.com, is a life sciences company focused

on the monitoring, detection and prevention of disease through continuous

biomedical signal monitoring. Signalife uses its patented signal technology

to develop medical devices that provide clear trusted data acquisition to

enable accurate timely diagnosis of heart disease. Signalife is publicly

traded on the American Stock Exchange under the symbol SGN. The website for

the company is http://www.signalife.com.



    Caution Regarding Forward-Looking Statement



    Statements in this release that are not strictly historical are

"forward- looking" statements. Forward-looking statements involve known and

unknown risks, which may cause Signalife's actual results in the future to

differ materially from expected results. Factors which could cause or

contribute to such differences include, but are not limited to, failure to

complete the development and introduction of heart monitoring and other

biomedical devices incorporating Signalife's technology, failure to obtain

federal or state regulatory approvals governing heart monitoring and other

biomedical devices incorporating Signalife's technology, inability to

obtain physician, patient or insurance acceptance of for heart monitoring

and other biomedical incorporating Signalife's technology, and the

unavailability of financing to complete management's plans and objectives,

including the development of heart monitoring and other biomedical

incorporating Signalife's technology. These risks are qualified in their

entirety by cautionary language and risk factors set forth and to be

further described in Signalife's filings with the Securities and Exchange

Commission.